

Anti-F9/Factor IX Antibody (Emicizumab)

Introduction

Emicizumab is a bispecific monoclonal antibody that links activated factor IX and activated factor X, replacing the function of the missing activated factor VIII and thus restoring hemostasis. Emicizumab is used in hemophilia A research.

Product parameters

Alternative Names	Hemlibra, ACE910, A44/B26
Target Accession	P00740
Target	F9 / Factor IX
CAS number	1610943-06-0
Molecular Weight	146.82 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG4
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	-
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

